Navigation Links
GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
Date:1/3/2008

sk Factors' in the Business and Prospects in the company's Annual Report on Form 20-F for 2006.

Theravance Forward-Looking Statements

This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to the goals, timing and expected results of clinical and preclinical studies, statements regarding the potential benefits and mechanisms of action of drug candidates, statements concerning the goals and timing of seeking regulatory approval of our product candidates, the enabling capabilities of Theravance's approach to drug discovery and its proprietary insights, statements concerning expectations for product candidates through development and commercialization and projections of revenue and other financial items. These statements are based on the current estimates and assumptions of the management of Theravance as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in its forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, the potential that results of clinical or preclinical studies indicate product candidates are unsafe, ineffective, inferior or not superior, and delays or failure to achieve regulatory approvals and risks of collaborating with third parties to develop and commercialize products. These a
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
2. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
3. GlaxoSmithKline Accelerates Review of Exelixis XL880
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
8. FASgen Announces a New Discovery in Obesity Research
9. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces New Discovery for Treatment of Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
(Date:7/21/2014)... July 21, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that it will host a ... to discuss results for the period ended June 30, ... with respect to its clinical program for aramchol. ...
(Date:7/21/2014)...   Aventura , the leader for instant-on ... that MemorialCare Health System , a top ... at the Orange Coast Memorial Medical Center ... Orange Coast Memorial is a 218-bed general medical ... annually. The Aventura Roaming Aware Desktop (RAD) – ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 3MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 4
... 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that ... Company's prostate cancer drug candidate CB7630,(abiraterone acetate) were ... Conference, which is currently taking place,in Lugano, Switzerland. ... presentations on Sunday, July 8, as part of ...
... Factor Xa Inhibitor,Shows a Significant Reduction in ... Enoxaparin with Similarly Low Bleeding,Rates , GENEVA, ... clinical trial,data presented today at the XXI ... demonstrate that once-daily,rivaroxaban (Xarelto®) achieved superior efficacy ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:7/22/2014)... 22, 2014 Recently, 2014quinceaneradresses.com, a popular ... its latest assortment of blue and white Quinceanera ... on these special Quinceanera gowns, hoping to show appreciation ... 30 can get a discounted price, up to 60% ... to announce these new items. As one of the ...
(Date:7/22/2014)... South Carolina (PRWEB) July 22, 2014 One ... loss solution managed to lose 20 pounds. Unfortunately, the weight ... and nauseated for the duration of her time using the ... One woman experienced heart flutters and insomnia as a result ... experienced a heart attack at the age of 37 because ...
(Date:7/22/2014)... IL (PRWEB) July 22, 2014 Hope ... of Matthew Baffoe to their Chicago staff. This addition ... Taff Construction Incorporated (TCI). Hope For The Warriors® is ... members, their families, and families of the fallen who ... of duty. , Baffoe’s work will support programs ...
(Date:7/22/2014)... Garland’s new Energizer BK specially ... as a flood coat over new and existing asphalt ... restoration material. It provides natural resistance to moisture, chemicals, ... life-cycle costs. Energizer BK is specially formulated with an ... in addition to superior strength and flexibility. , ...
(Date:7/22/2014)... July 22, 2014 The hair ... are now offering robotic assisted laser therapy and ... solutions for men and women suffering from hair ... they now offer Follicular Unit Extraction (FUE) procedures ... robot. With this new technology, their doctors use ...
Breaking Medicine News(10 mins):Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2Health News:Hope For The Warriors Builds on Staff and Office Space in Chicago to Support Career Transition for Vets 2Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2
... pro-health messages can predict if you,ll keep that resolution ... That,s according to a new study forthcoming in ... who were already taking action to quit," says Emily ... of the Communication Neuroscience Laboratory at the U-M Institute ...
... to develop computer-assisted diagnosis tools that will provide ... consistently accurate diagnoses. "The advent of digital ... revolution in imaging technology for histopathology," according to ... Biomedical Informatics at The Ohio State University Medical ...
... the counter has not reduced the number of teenage ... sexually-transmitted diseases (STIs), according to a report by experts ... and Sourafel Girma used local health authority data to ... to offer emergency birth control at pharmacies and without ...
... Having sex while you,re pregnant is generally safe, a new ... review authors. "There are very few proven contraindications and risks ... be reassured." The primer, based on a review of ... Medical Association Journal . Some potential, but uncommon, risks ...
... to build an extra natural layer of nanoparticle-like armour has ... startlingly simple way to give drug bearing polymer vesicles (microscopic ... The Warwick researchers have been able to decorate these ... strategy in the design of vehicles for drug release, for ...
... Scientists have discovered why orchids are one of the most ... to their relationships with the bees that pollinate them and ... the American Naturalist , is the culmination of a ... College London, the Royal Botanic Gardens, Kew, and other international ...
Cached Medicine News:Health News:Resolved to quit smoking? 2Health News:Computer-assisted diagnosis tools to aid pathologists 2Health News:Computer-assisted diagnosis tools to aid pathologists 3Health News:Morning after pill linked to increase in STIs, study shows 2Health News:Morning after pill linked to increase in STIs, study shows 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 3
... contain a buffered sodium citrate ... a citrate concentration of 0.109 ... (3.8%). The mixing ratio is ... 9 parts blood. In addition ...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
Medicine Products: